ES2238277T3 - Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5. - Google Patents

Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5.

Info

Publication number
ES2238277T3
ES2238277T3 ES00928604T ES00928604T ES2238277T3 ES 2238277 T3 ES2238277 T3 ES 2238277T3 ES 00928604 T ES00928604 T ES 00928604T ES 00928604 T ES00928604 T ES 00928604T ES 2238277 T3 ES2238277 T3 ES 2238277T3
Authority
ES
Spain
Prior art keywords
alkyl
phenyl
hydrogen
group
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00928604T
Other languages
English (en)
Spanish (es)
Inventor
Mark A. Laughlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2238277T3 publication Critical patent/ES2238277T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES00928604T 1999-05-04 2000-05-01 Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5. Expired - Lifetime ES2238277T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
US304897 1999-05-04

Publications (1)

Publication Number Publication Date
ES2238277T3 true ES2238277T3 (es) 2005-09-01

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00928604T Expired - Lifetime ES2238277T3 (es) 1999-05-04 2000-05-01 Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5.

Country Status (21)

Country Link
EP (1) EP1175224B1 (https=)
JP (1) JP2002543144A (https=)
CN (1) CN1349408A (https=)
AR (1) AR023824A1 (https=)
AT (1) ATE289516T1 (https=)
AU (1) AU776541B2 (https=)
BR (1) BR0010593A (https=)
CA (1) CA2365900A1 (https=)
DE (1) DE60018273T2 (https=)
ES (1) ES2238277T3 (https=)
HK (1) HK1039278B (https=)
HU (1) HUP0202734A3 (https=)
MX (1) MXPA01011116A (https=)
MY (1) MY127670A (https=)
NO (1) NO328679B1 (https=)
NZ (1) NZ514519A (https=)
PE (1) PE20010283A1 (https=)
PT (1) PT1175224E (https=)
TW (1) TWI289454B (https=)
WO (1) WO2000066141A2 (https=)
ZA (1) ZA200108870B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
US20070043079A1 (en) * 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
EP1790637B1 (en) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
JP4769257B2 (ja) * 2005-02-23 2011-09-07 シェーリング コーポレイション ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
BR112016015736B1 (pt) * 2014-01-08 2022-01-04 Immunovative Therapies, Ltd. Uso de um aloantígeno, uma molécula que interage com receptor de superfície cd40 e citocinas tipo i; e pelo menos um ou mais antígenos de hiv, kit, composição e composição de avi
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
AU5522498A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
JP2002543144A (ja) 2002-12-17
DE60018273T2 (de) 2005-08-18
MY127670A (en) 2006-12-29
HUP0202734A3 (en) 2003-11-28
PT1175224E (pt) 2005-07-29
NO328679B1 (no) 2010-04-26
ZA200108870B (en) 2003-03-26
HUP0202734A2 (hu) 2002-12-28
TWI289454B (en) 2007-11-11
EP1175224B1 (en) 2005-02-23
BR0010593A (pt) 2002-02-13
EP1175224A2 (en) 2002-01-30
PE20010283A1 (es) 2001-03-16
HK1039278B (en) 2005-06-30
NO20015367L (no) 2002-01-03
CA2365900A1 (en) 2000-11-09
WO2000066141A3 (en) 2001-02-08
AR023824A1 (es) 2002-09-04
AU4681500A (en) 2000-11-17
AU776541B2 (en) 2004-09-16
DE60018273D1 (de) 2005-03-31
NO20015367D0 (no) 2001-11-02
HK1039278A1 (en) 2002-04-19
WO2000066141A2 (en) 2000-11-09
ATE289516T1 (de) 2005-03-15
MXPA01011116A (es) 2002-06-04
NZ514519A (en) 2003-07-25
CN1349408A (zh) 2002-05-15

Similar Documents

Publication Publication Date Title
ES2238277T3 (es) Terapia anti-vih con una combinacion de un interferon alfa-pegilado y un antagonista de ccr5.
ZA200307474B (en) CCR5 antagonists useful for treating AIDS.
US6635646B1 (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
US20020004584A1 (en) HIV immune adjuvant therapy
US20070123538A1 (en) Compositions comprising a combination of CCR5 and CXCR4 antagonists
CN1481251A (zh) 治疗病毒感染的联合方法
EP1034790A2 (en) HIV therapy
US20020182179A1 (en) HIV Therapy
HK1027286A (en) Hiv therapy
AU2002245148A1 (en) CCR5 antagonist and DP-178 polypeptide for treating viral infections
MX2008007042A (en) Compositions comprising a combination of ccr5 and cxcr4 antagonists